About Amy Martin, Vice President, Access Experience Team

This author has not yet filled in any details.
So far Amy Martin, Vice President, Access Experience Team has created 2 blog entries.

Will the US Move Away from Interchangeable Designations for Biosimilars?

On September 15, 2023, the Food and Drug Administration released draft guidance entitled “Labeling for Biosimilar and Interchangeable Biosimilar Products.” The agency is accepting comments through November 17, 2023, and the finalized guidance will revise and replace the 2018 guidance for the industry entitled “Labeling for Biosimilar Products.” 

The Growing Emergence of Biosimilars

After a slow start since the first US biosimilar came to market in 2015, there has been a significant increase in approvals and launches. To date, 41 have been approved in the US, with over 90 biosimilars in development. Additionally, in the upcoming months, several biosimilar launches are anticipated to meaningfully impact formularies and pharmacy benefit specialty drug spend.